Most Recent
It ditched a planned $627 million union, now US drug maker Cosette must pay more than $13 million toward Mayne Pharma's costs of the legal fallout. Whether it owes the "substantial damages" Mayne is claiming is an issue for another day.
Cosmetic surgeon Dr Daniel Lanzer wants to strip a case of class action status, arguing claims he and other doctors passed themselves off as plastic surgeons were not suitable for a group proceeding.
Sydney's St Vincent’s Hospital says the doctor leading a class action over alleged unpaid overtime can't bring the case because she did not file overtime claims.
Mayne Pharma cannot access invoices from Cosette’s solicitors at Corrs Chambers Westgarth, with a judge saying he was not hopeful that they would help to resolve a costs fight related to litigation over their collapsed $672 million merger.
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.
A Western Australian couple has sued fertility services provider Monash IVF after the company implanted a woman with a different embryo than the one they had donated.
Pharmacor has accused AstraZeneca of launching a royal commission into emails with its lawyers as AstraZeneca opposes the generic drug maker's bid to amend its pleading in a patent case over diabetes drug Forxiga.
US drug maker Pfizer has been hit with a class action alleging it knew or ought to have known about the increased risk that patients who used its injectable contraceptive Depo-Provera could develop brain tumors.
A judge has said women who donated eggs to their same-sex partners and were removed from a class action over IVF rebates could potentially revive their claims, but the lead applicant has not yet indicated whether she will pursue this path.